The Evidence Gap: Palantir's NHS Claims Face Scrutiny Over 'Cause and Effect'
AI-generated image · US National Wire
As NHS England seeks to verify the benefits of the Federated Data Platform, the lack of independent clinical audits leaves a wide opening for vaporware concerns.
In the world of health tech, there is a profound difference between a software tool being deployed and a clinical outcome being improved. For Palantir, the company currently leading the consortium for the UK's Federated Data Platform (FDP), that distinction has become the center of a growing dispute over how success is measured in the National Health Service (NHS), as first reported by The Register.
According to reporting from The Register, NHS England CEO Sir Jim Mackey has indicated plans to notify Palantir that any future claims regarding the benefits of the FDP must be cleared through his team first. This move comes amid concerns that the company is attributing systemic improvements directly to its software without sufficient evidence. Labour MP Ben Coleman noted to the Health and Social Care Committee that while NHS England had previously cautioned against attributing improvements directly to the platform, Tom Watson—the newly appointed senior vice president for Palantir UK—has claimed that Palantir is making a difference and is responsible for the changes taking place.
***
**Opinion: The Vaporware Warning**
From my perspective as a tech columnist, these dynamics are a classic red flag. When a vendor claims victory based on self-reported metrics while the client admits it cannot prove cause and effect, you are no longer looking at a clinical success story; you are looking at potential vaporware. Until independent clinical audits prove that these tools—rather than staffing changes or operational shifts—are the primary drivers of patient outcomes, Palantir's 'wins' remain anecdotal.
***
**The Data Disconnect**
The friction over these claims is rooted in a significant gap between Palantir's narrative and the available data. As reported by The Register, NHS England previously stated that as of June, 139 trusts were using the platform, with 137 of those reporting benefits. Specifically, the FDP-based Inpatient Care Coordination Solution was credited with helping hospitals perform procedures on an additional 111,589 patients.
However, the validity of these figures has been challenged. A Freedom of Information request revealed that nearly a third of the NHS trusts using the health data platform were actually performing fewer patient procedures than they were before the system went live.
Furthermore, the Office for Statistics Regulation (OSR) has stepped in to examine the evidence. The OSR noted that NHS England acknowledged the need to communicate FDP performance claims more clearly. On its own website, NHS England published a caveat stating it could not draw conclusions regarding cause and effect because other variables had not been controlled for.
**The Defense of the FDP**
Tom Watson has attempted to rebut what he describes as misinformation. In a statement on X, Watson acknowledged the OSR's point that no study has yet been conducted on the FDP that controls for external factors, such as industrial action or changes in staffing levels, calling it a "fair note of caution."
In a prepared video, Watson highlighted specific institutions—including Chelsea and Westminster Hospital, University Hospitals of Derby and Burton, and Northampton General Hospital—as having produced figures showing they benefit from the platform. While Watson admitted in the video that Palantir cannot prove every single procedure happened because of the software, he argued that the reports from the hospitals themselves should not be ignored.
**The Enforcement Problem**
Despite the desire for more rigorous verification, the ability of the NHS to police these claims is questionable. Sir Jim Mackey admitted to the Health and Social Care Committee that while he intends to tell Palantir to clear future benefit claims, such a requirement may be "hard to enforce" contractually.
This lack of oversight is particularly pressing given the timeline of the current contract, which was awarded in November 2023 for £330 million and is set to end in March 2027. While NHS England did award a contract to Imperial College Projects in February 2026 to independently evaluate the FDP, The Register reports that these findings are not expected until after ministers have already decided whether to extend the Palantir contract.
Until that independent evaluation is complete, the FDP exists in a state of evidentiary limbo: touted by its creators as a success, but lacking the controlled, audited proof required to confirm it is actually saving lives or improving efficiency.